Public Health & Policy
FDA General
More in FDA General
Members push aside data concerns, endorse retinoid for fibrodysplasia ossificans progressiva
Jun 29, 2023
Challenges of drug development in fibrodysplasia ossificans progressiva on full display
Jun 27, 2023
Ritlecitinib led to 80% scalp coverage at 6 months in nearly a fourth of adolescents and adults
Jun 26, 2023
Warrior Labz SARMS markets several drugs they claim could address weight loss, muscle growth
Jun 22, 2023
Repurposed anti-inflammatory drug may be used alone or in combination with standard meds
Jun 20, 2023
Continuing Medical Education
1.00 CME Credits
0.50 CME Credits